Edwin Kwok

Practice Areas

Edwin Kwokis a leading Corporate and Capital Markets lawyer with extensive experience advising major investment banks, healthcare and TMT issuers, life science and biotech firms, Chinese state-owned enterprises, real estate and property management companies on their initial public offerings, cross-border acquisitions, public takeovers, privatizations, spin-offs, corporate compliance, SFC’s licensing and follow-on offerings of equity and debt securities.

Edwin has extensive experience includes advising on some of the most significant capital markets and mergers and acquisitions transactions in the Asia region. He has advised on numerous securities offerings on the Hong Kong Stock Exchange, public takeovers and listing rules regulated notifiable transactions, some of which were highly complex involving complicated cross border implications. He has represented a number of biotech and healthcare companies in their listings on the Main Board of the Hong Kong Stock Exchange, including RemeGen, Akeso, Brii Biosciences, Pharmaron Beijing, Peijia Medical, Honliv Healthcare Management, Cryofocus Medtech, Jenscare Scientific, Acotec Scientific, Shanghai Bio-heart, Shanghai HeartCare Medical, KeyMed Biosciences, Jacobio Pharmaceuticals, Hygeia Health, and Simcere Pharmaceutical. He is also deeply experienced with privatizations and takeovers of Hong Kong listed companies.

Before founding Edwin Kwok and Co, Edwin was a partner at O’Melveny & Myers and Paul Hastings. He has led in building and positioning O’Melveny & Myers as the market leader for life science and biotech capital markets transactions following the adoption by the Hong Kong Stock Exchange of Chapter 18A into its listing rules.

Expert in these Jurisdictions

Hong Kong and England & Wales

Awards